SynthesisZeitschrift fur Rheumatologie2019
Overall and sex- and disease subtype-specific mortality in patients with systemic sclerosis : An updated meta-analysis.
Synthesis in Zeitschrift fur Rheumatologie, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Comparative Efficacy of Autologous Hematopoietic and Mesenchymal Stem Cell Transplantation in Patients with Systemic Sclerosis: A Systematic Review.Journal of clinical medicine · 2025Review
- A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018-2024.Current opinion in rheumatology · 2025Article
- Prevalence, incidence, and mortality of Raynaud's phenomenon, Sjögren's syndrome and scleroderma: an umbrella review of systematic reviews.Rheumatology advances in practice · 2024Review
- A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis.Clinical reviews in allergy & immunology · 2023Review
- Particularly severe form of refractory gastrointestinal involvement in systemic sclerosis.BMJ case reports · 2023Article
- Secular Trends in Systemic Sclerosis Mortality in the United States from 1981 to 2020.International journal of environmental research and public health · 2022Article
- Overall mortality.Journal of scleroderma and related disorders · 2021Article
- Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort.Arthritis research & therapy · 2020Article
- Estradiol levels are elevated in older men with diffuse cutaneous SSc and are associated with decreased survival.Arthritis research & therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the overall and sex- and disease subtype-specific standardized mortality ratios (SMRs) in patients with systemic sclerosis (SSc).
methodsWe surveyed studies examining overall and sex- and disease subtype-specific SMRs in patients with SSc compared with the general population using MEDLINE, EMBASE, and Cochrane databases and manual searches. A meta-analysis of the overall and sex- and disease subtype-specific SMRs in patients with SSc was then performed.
resultsOverall, 22 reports including 13,214 patients with SSc, with 4218 deaths, met the inclusion criteria. Compared to that in the general population, overall SMR was increased in patients with SSc (SMR 2.823, 95% confidence interval [CI] 2.219-3.591, p < 0.001). Stratification by region showed a significant increase in SMR in European, North American, Asian, and Oceanian populations. Sex-specific meta-analysis revealed a significant increase in overall SMR in women and men (SMR 2.929, 95% CI 2.504-3.427, p < 0.001; SMR 3.523, 95% CI 2.933-4.232, p < 0.001), with no difference in the SMR between men and women. Disease subtype-specific meta-analysis revealed a significant increase in SMR in limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc), however, the SMR was higher in dcSSc (SMR 4.865, 95% CI 3.863-6.127, p < 0.001) than in lcSSc (SMR 2.020, 95% CI 1.570-2.599, p < 0.001).
conclusionWe demonstrate that patients with SSc have 2.82-fold higher mortality rates than the general population and that the overall SMR does not depend on sex, region, and disease subtype, however, mortality is significantly higher in dcSSc than in lcSSc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.